Biomarker-guided antibiotic therapy in adult critically ill patients: A critical review

Annals of Intensive Care

Volumn 2, Issue 1, 2012, Pages

  Póvoa, Pedro ^a,b   Salluh, Jorge I F ^c,d  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Antibiotic stewardship; Biomarkers; C reactive protein; Infection; Procalcitonin; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN;

ALGORITHM; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; CRITICALLY ILL PATIENT; HORMONE BLOOD LEVEL; HOSPITAL INFECTION; HUMAN; IMMUNOASSAY; INFECTION RATE; INTENSIVE CARE; LENGTH OF STAY; LIMIT OF DETECTION; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT COMPLIANCE; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SUPERINFECTION; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84866122633     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-2-32     Document Type: Review

References (50)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Agency for Healthcare Research and Quality: Diagnostic groups with rapidly increasing costs by payer. 2001-2007. HCUP statistical brief 91. http://www.hcupus.ahrq.gov/reports/statbriefs/sb91.pdf.
4. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc 2007, 9:8-18.
5. Povoa PR, Carneiro AH, Ribeiro OS, Pereira AC: Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study). Crit Care Med 2009, 37:410-416.
6. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010, 36:222-231.
7. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866.
8. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
9. Weiss CH, Moazed F, McEvoy CA, Singer BD, Szleifer I, Amaral LA, Kwasny M, Watts CM, Persell SD, Baker DW, Sznajder JI, Wunderink RG: Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. Am J Respir Crit Care Med 2011, 184:680-686.
10. Christ-Crain M, Opal SM: Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203.
11. Pierrakos C, Vincent JL: Sepsis biomarkers: a review. Crit Care 2010, 14:R15.
12. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
13. Povoa P: Serum markers in community-acquired pneumonia and ventilatorassociated pneumonia. Curr Opin Infect Dis 2008, 21:157-162.
14. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher CJ Jr, Faist E, Reinhart K: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003, 31:1560-1567.
15. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
16. Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
17. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
18. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
19. Hogarth MB, Gallimore R, Savage P, Palmer AJ, Starr JM, Bulpitt CJ, Pepys MB: Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age Ageing 1997, 26:153-158.
20. Jaye DL, Waites KB: Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997, 16:735-746.
21. Povoa P: C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002, 28:235-243.
22. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993, 91:1351-1357.
23. Dahaba AA, Rehak PH, List WF: Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003, 29:579-583.
24. Salluh JI, Soares M, Coelho LM, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, eSilva JR, Bozza PT, Povoa P: Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011, 26:193-200.
25. Povoa P, Souza-Dantas VC, Soares M, Salluh JF: C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care 2011, 15:R129.
26. Reinhart K, Karzai W, Meisner M: Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000, 26:1193-1200.
27. Oberhoffer M, Vogelsang H, Jager L, Reinhart K: Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care 1999, 14:29-33.
28. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994, 79:1605-1608.
29. Brunkhorst FM, Heinz U, Forycki ZF: Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 1998, 24:888-889.
30. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C: Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 2006, 43:468-473.
31. Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand M, Coriat P, Riou B, Bernard M, Hausfater P: Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008, 36:1147-1154.
32. Mongardon N, Lemiale V, Perbet S, Dumas F, Legriel S, Guerin S, Charpentier J, Chiche JD, Mira JP, Cariou A: Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients. Intensive Care Med 2010, 36:92-99.
33. Dahaba AA, Elawady GA, Rehak PH, List WF: Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002, 30:269-274.
34. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington: The National Academies Press; 2010.
35. Gill CW, Bush WS, Burleigh WM, Fischer CL: An evaluation of a C-reactive protein assay using a rate immunonephelometric procedure. Am J Clin Pathol 1981, 75:50-55.
36. Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA: Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001, 27:211-215.
37. Snider RH Jr, Nylen ES, Becker KL: Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997, 45:552-560.
38. Christ-Crain M, Muller B: Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Wkly 2005, 135:451-460.
39. Christ-Crain M, Muller B: Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007, 30:556-573.
40. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B: Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010, 8:575-587.
41. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505.
42. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
43. Svoboda P, Kantorova I, Scheer P, Radvanova J, Radvan M: Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology 2007, 54:359-363.
44. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009, 394:221-226.
45. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375.
46. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83.
47. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058.
48. Miller FG, Silverman HJ: The ethical relevance of the standard of care in the design of clinical trials. Am J Respir Crit Care Med 2004, 169:562-564.
49. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M: Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602.
50. Gibot S: Procalcitonin in intensive care units: the PRORATA trial. Lancet 2010, 375:1605-1606. author reply 1606-1607.